Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity

v3.8.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income [Member]
Retained Earnings [Member]
Balance at Dec. 31, 2014 $ 22,800 $ 0 $ 15 $ 94,586 $ 0 $ (71,801)
Balance (in shares) at Dec. 31, 2014   0 14,517      
Issuance of common stock, net of underwriting discount & issuance costs 14,218 $ 0 $ 0 14,218 0 0
Issuance of common stock, net of underwriting discount & issuance costs (in shares)   15 0      
Allocation of proceeds from Series A preferred stock to warrant liability (11,700) $ 0 $ 0 (11,700) 0 0
Beneficial conversion feature on Series A preferred stock 3,300 0 0 3,300 0 0
Conversion of Series A convertible preferred stock to common stock and accretion of Series A convertible preferred stock discount 1,356 $ 0 $ 0 1,356 0 0
Conversion of Series A convertible preferred stock to common stock and accretion of Series A convertible preferred stock discount (in shares)   (2) 246      
Deemed dividend on Series A convertible preferred stock (4,655) $ 0 $ 0 (4,655) 0 0
Issuance of common stock for assets acquired from Equipois 1,071 $ 0 $ 0 1,071 0 0
Issuance of common stock for assets acquired from Equipois (in shares)   0 112      
Issuance of common stock upon exercise of warrants 53 $ 0 $ 0 53 0 0
Issuance of common stock upon exercise of warrants (in shares)   0 7      
Issuance of common stock upon exercise of stock options 225 $ 0 $ 0 225 0 0
Issuance of common stock upon exercise of stock options (in shares)   0 145      
Stock-based compensation expense 1,731 $ 0 $ 0 1,731 0 0
Net loss (19,590) 0 0 0 0 (19,590)
Foreign currency translation adjustments (1) 0 0 0 (1) 0
Balance at Dec. 31, 2015 8,808 $ 0 $ 15 100,185 (1) (91,391)
Balance (in shares) at Dec. 31, 2015   13 15,027      
Shares issued as a result of rounding due to reverse-stock split 0 $ 0 $ 0 0 0 0
Shares issued as a result of rounding due to reverse-stock split (in shares)   0 8      
Issuance of common stock, net of underwriting discount & issuance costs 14,694 $ 0 $ 4 14,690 0 0
Issuance of common stock, net of underwriting discount & issuance costs (in shares)   0 4,017      
Conversion of Series A convertible preferred stock to common stock and accretion of Series A convertible preferred stock discount 10,345 $ 0 $ 3 10,342 0 0
Conversion of Series A convertible preferred stock to common stock and accretion of Series A convertible preferred stock discount (in shares)   (13) 2,310      
Deemed dividend on Series A convertible preferred stock (10,345) $ 0 $ 0 (10,345) 0 0
Issuance of common stock upon exercise of warrants 3,188 $ 0 $ 0 3,188 0 0
Issuance of common stock upon exercise of warrants (in shares)   0 488      
Issuance of common stock upon exercise of stock options 110 $ 0 $ 0 110 0 0
Issuance of common stock upon exercise of stock options (in shares)   0 44      
Stock-based compensation expense 3,121 $ 0 $ 0 3,121 0 0
Net loss (23,470) 0 0 0 0 (23,470)
Foreign currency translation adjustments 80 0 0 0 80 0
Balance at Dec. 31, 2016 6,531 $ 0 $ 22 121,291 79 (114,861)
Balance (in shares) at Dec. 31, 2016   0 21,894      
Issuance of common stock, net of underwriting discount & issuance costs 11,058 $ 0 $ 4 11,054 0 0
Issuance of common stock, net of underwriting discount & issuance costs (in shares)   0 3,732      
Equipois supply and sales earn-outs 237 $ 0 $ 0 237 0 0
Equipois supply and sales earn-outs (in shares)   0 90      
Issuance of common stock, net of issuance costs of $227 33,773   $ 34 33,739 0 0
Issuance of common stock, net of issuance costs of $227 (in shares)     34,000      
Allocation of proceeds from Series A preferred stock to warrant liability (3,301) $ 0 $ 0 (3,301) 0 0
Issuance of common stock upon exercise of warrants 174 $ 0 $ 0 174 0 0
Issuance of common stock upon exercise of warrants (in shares)   0 30      
Issuance of common stock upon exercise of stock options 46 $ 0 $ 0 46 0 0
Issuance of common stock upon exercise of stock options (in shares)   0 82      
Issuance of restricted stock 0 $ 0 $ 0 0 0 0
Issuance of restricted stock (in shares)   0 115      
Stock-based compensation expense 2,414 $ 0 $ 0 2,414 0 0
Net loss (29,122) 0 0 0 0 (29,122)
Cumulative retrospective adjustment to retained earnings for ASU 2016-09 adoption 0 0 0 171 0 (171)
Foreign currency translation adjustments (419) 0 0 0 (419) 0
Balance at Dec. 31, 2017 $ 21,391 $ 0 $ 60 $ 165,825 $ (340) $ (144,154)
Balance (in shares) at Dec. 31, 2017   0 59,943